Serum suPAR and syndecan-4 levels predict severity of community-acquired pneumonia: a prospective, multi-centre study

Table 3 Area under the curve (AUC) and thresholds for predicting total mortality in patients with SCAP

	Threshold	Sensitivity (%)	Specificity (%)	AUC	p value	95% CI
	Threshold	Sensitivity (%)	Specificity (%)	AUC	p value	Lower limit	Higher limit
suPAR (ng/mL)	≥10.22	68.23%	89.29%	0.772	<0.001	0.636	0.908
Syndecan-4 (ng/mL)	≤6.68	73.68%	71.43%	0.744	<0.001	0.618	0.870
WBC (×10⁹/L)	>16.40	36.84%	83.33%	0.558	0.489	0.393	0.723
NLR	>15.77	52.63%	71.95%	0.565	0.424	0.405	0.726
CRP (mg/L)	>164.15	42.86%	73.97%	0.533	0.701	0.363	0.703
PCT (μg/L)	>0.34	85.71%	41.56%	0.618	0.137	0.462	0.774
CURB-65	>1	68.42%	64.29%	0.723	<0.001	0.607	0.839
PSI	>113	78.95%	75.90%	0.787	<0.001	0.675	0.898
APACHE II	>14	84.21%	60.71%	0.743	<0.001	0.636	0.851

SCAP severe community-acquired pneumonia, suPAR soluble urokinase-type plasminogen activator receptor, WBC whole blood leukocyte count, NLR neutrophil/lymphocyte ratio, CRP C-reactive protein, PCT procalcitonin, CURB-65 confusion, urea, respiratory rate, blood pressure, and age ≥65 years old score, PSI Pneumonia Severity Index score, APACHE II Acute Physiology and Chronic Health Evaluation II score